Clinical trials: Pseudomonas Infections
Pseudomonas Aeruginosa
Pathobiomes in Gut of Critically Ill Patients
Despite powerful antibiotics, 50% of the intestinal tracts of critically ill surgical patients are colonized by Pseudomonas aeruginosa, whose mere presence in this site increases mortality fourfold by mechanisms that remain…
- Trial name
- NCT06822465
- Testing
- P. aeruginosa using in vitro and in vivo assays
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Pseudomonas Infections, Pseudomonas Aeruginosa
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as…
- Conditions
- Pseudomonas Infections, Pseudomonas Aeruginosa, Prognosis, Drug Resistance, Multiple, Bacterial
- Trial name
- ADDICT (NCT06738771)
- Where
- 48 sites in France, Reunion
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
The purpose of this study was to evaluate the safety and efficacy of multiple courses of AZLI in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF3 (NCT00128492)
- Testing
- AZLI 75 mg two times a day (BID)/ three times a day (TID)
- Where
- 65 sites in United States, Australia and 2 more
- Volunteers
- 274 people
- Sponsor
- Gilead Sciences
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria
The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in pediatric participants with new onset Pseudomonas aeruginosa…
- Trial name
- ALPINE 2 (NCT03219164)
- Testing
- AZLI
- Where
- 53 sites in United States, Austria and 10 more
- Volunteers
- 149 people
- Sponsor
- Gilead Sciences
Septic Shock
Pentaglobin in CRE and PA Neutropenic Infections
To demonstrate that the early addition of Pentaglobin to the best available antimicrobial therapy is able to reduce mortality and improve survival in neutropenic febrile acute leukemia or allo- Hematopoietic stem cell…
- Trial name
- PENTALLO (NCT03494959)
- Testing
- Pentaglobin
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Cystic Fibrosis
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
The purpose of this study is to assess the efficacy of IV gallium to improve pulmonary function as measured by a 5% or greater relative improvement in forced expiratory volume in one second (FEV1) from baseline to Day 28.
- Trial name
- NCT02354859
- Testing
- Gallium nitrate, Normal Saline
- Where
- 23 sites in United States
- Volunteers
- 119 people
- Sponsor
- University of Washington
Bladder Cancer
Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
This is a multicenter, single-arm study to evaluate the efficacy and safety of Pseudomonas aeruginosa the treatment of patients with intermediate and high risk non-muscle invasive bladder cancer.
- Trial name
- NCT05975151
- Testing
- Pseudomonas aeruginosa
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Qilu Hospital of Shandong University
Healthy
Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers
The objective is to confirm the optimal dose of IC43 in regard to immunogenicity, safety and tolerability.
- Trial name
- NCT00778388
- Testing
- IC43
- Where
- 3 sites in Austria, Germany
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Cystic Fibrosis
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
The purpose of this trial is to compare the effects of treatment with tobramycin solution for inhalation (TIS) with and without azithromycin in people with cystic fibrosis (CF) age 6 months to 18 years who have early isolation of…
- Trial name
- OPTIMIZE (NCT02054156)
- Testing
- azithromycin, Tobramycin solution for inhalation
- Where
- 45 sites in United States
- Volunteers
- 221 people
- Sponsor
- Bonnie Ramsey
Pseudomonas Aeruginosa, Cystic Fibrosis
The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis
Pseudomonas aeruginosa (Pa) is the bacterium that causes one of the most consequential lung infections in people with CF. Many young children do not have Pa in their lungs but will become infected as they get older.
- Trial name
- NCT01616862
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Zafer Soultan
Cystic Fibrosis
Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa
The primary objective of this study is to evaluate the safety and tolerability of a single dose of KB001 in Cystic Fibrosis patients infected with Pseudomonas aeruginosa (Pa)
- Trial name
- NCT00638365
- Testing
- KB001
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Humanigen, Inc.
Pneumonia - Bacterial, Pseudomonas Aeruginosa Infection
MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MP101 administered in addition to standard antibiotic therapy in adult patients with acute Pseudomonas aeruginosa pneumonia.
- Trial name
- MP101-1001 (NCT07492771)
- Testing
- MP101, Antibiotics
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- MicrobiotiX Co., Ltd
Mesothelioma
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
Background: Standard therapy for mesothelioma is a combination of the drugs pemetrexed and cisplatin. However, the benefits of this treatment are limited, and in most treated patients the disease continues to worsen.
- Trial name
- NCT01445392
- Testing
- Multicycle SS1P, Pemetrexed, Cisplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Trauma, Resistant Infection
Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens
The purpose of this study is to assess the safety and efficacy of polymyxin B as monotherapy versus a combined polymyxin B-carbapenem therapy against multidrug-resistant (MDR) gram negative infections.
- Conditions
- Trauma, Resistant Infection, Critical Illness
- Trial name
- MUSEUM (NCT03159078)
- Testing
- Polymyxin B
- Where
- Puerto Rico
- Volunteers
- 40 people
- Sponsor
- University of Puerto Rico
Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Cystic fibrosis (CF) is a chronic disease that significantly affects an individual's lung function. Antibiotic medications have been proven effective at reducing Pseudomonas aeruginosa (PA) infection, which is one of the main…
- Trial name
- EPIC (NCT00097773)
- Testing
- Tobramycin solution for inhalation (TOBI), Oral ciprofloxacin
- Where
- 54 sites in United States
- Volunteers
- 304 people
- Sponsor
- Seattle Children's Hospital
Cystic Fibrosis, Pseudomonas Aeruginosa
A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies
This is a pilot study of inhaled antibiotic regimens is a pilot study examining clinical and laboratory endpoints of patients on inhaled antibiotic treatments.
- Trial name
- NCT01319253
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Indiana University
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A reduces sputum Pseudomonas aeruginosa (PsA) bacterial load in CF subjects with…
- Trial name
- NCT05010577
- Testing
- BX004-A
- Where
- 28 sites in United States, Czechia and 3 more
- Volunteers
- 43 people
- Sponsor
- BiomX, Inc.
Pseudomonas Aeruginosa, Multi-antibiotic Resistance
Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.
- Trial name
- ABAC-IBS (NCT04335383)
- Testing
- Isolation of anti-Pseudomonas antibodies from type B lymphocytes
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Grenoble
Cystic Fibrosis in Adults, Chronic Colonization With Pseudomonas Aeruginosa
Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution
In cystic fibrosis, there is a critical need for better predictors of treatment response. The investigators have identified a panel of white blood cell biomarkers which can be directly measured as a blood test in subjects with…
- Trial name
- NCT01736839
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Jewish Health
Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa
Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
This study is planned to evaluate the safety and efficacy of the drug Ftortiazinon in combination with the drug Maxipime® in comparison with placebo in combination with the drug Maxipime® in the treatment of hospitalized adult…
- Conditions
- Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa, Pseudomonas Aeruginosa, Pseudomonas Infections, Urinary Tract Infections
- Trial name
- NCT03638830
- Testing
- Ftortiazinon (tablets 300 mg) full dose + Maxipim
- Where
- 5 sites in Russia
- Volunteers
- 777 people
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation